首页> 外文OA文献 >Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC

【2h】

Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC

机译：CD31评估的微血管密度预测北伐单抗治疗在转移性结肠直肠癌中的临床益处：热情研究的结果，翻译前期研究Capecitabine和Irinotecan Plus Bevacizumab，然后是Capecitabine和Oxaliplatin加贝伐单抗或MCRC患者的逆向序列

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Daniela Bianconi; Merima Herac; Florian Posch; Margit Schmeidl; Matthias Unseld; Markus Kieler; Robert Brettner; Leonhard Müllauer; Jakob Riedl; Armin Gerger; Werner Scheithauer; Gerald Prager;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable|[sol]|metastatic colorectal cancer (mCRC) [J] . J Souglakos, N Ziras, S Kakolyris, British Journal of Cancer . 2012,第3期

机译：CAPIRI（卡培他滨，伊立替康）加贝伐单抗与FOLFIRI（亚叶酸，5-氟尿嘧啶，伊立替康）加贝伐单抗的II期随机试验作为一线治疗不可切除的结肠癌（mCRC）患者
2. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study) [J] . DucreuxM., AdenisA., PignonJ.-P., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2013,第6期

机译：以贝伐单抗为基础的联合方案对先前未治疗的转移性结直肠癌患者的疗效和安全性：贝伐单抗+ 5-氟尿嘧啶，亚叶酸钙+伊立替康与贝伐单抗+卡培他滨+伊立替康的ii期随机研究的最终结果（FNCLCC ACCORD 13/0503研究）
3. Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70?years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG) [J] . Lambros Vamvakas, Alexios Matikas, Athanasios Karampeazis, BMC Cancer . 2014,第1期

机译：卡培他滨联合奥沙利铂和贝伐单抗（AXELOX）作为转移性结直肠癌（mCRC）的适应性和弱势老年患者（年龄> 70岁）的一线治疗：希腊肿瘤研究组（HORG）的多中心II期研究
4. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
5. Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC [O] . Daniela Bianconi, Merima Herac, Florian Posch, 2020

机译：CD31评估的微血管密度预测北伐单抗治疗在转移性结肠直肠癌中的临床益处：热情研究的结果翻译前期研究Capecitabine和Irinotecan Plus Bevacizumab然后是Capecitabine和Oxaliplatin加贝伐单抗或MCRC患者的逆向序列
6. Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG) [O] . Lambros Vamvakas, Alexios Matikas, Athanasios Karampeazis, 2014

机译：卡培他滨联合奥沙利铂和贝伐单抗（AXELOX）作为适合和脆弱的转移性结直肠癌（mCRC）老年患者（年龄> 70岁）的一线治疗：希腊肿瘤研究组（HORG）的多中心II期研究

著录项

引文网络

相似文献

相关主题

期刊订阅